195 related articles for article (PubMed ID: 10706127)
1. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
Cuny M; Kramar A; Courjal F; Johannsdottir V; Iacopetta B; Fontaine H; Grenier J; Culine S; Theillet C
Cancer Res; 2000 Feb; 60(4):1077-83. PubMed ID: 10706127
[TBL] [Abstract][Full Text] [Related]
2. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL
Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
4. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
Courjal F; Cuny M; Simony-Lafontaine J; Louason G; Speiser P; Zeillinger R; Rodriguez C; Theillet C
Cancer Res; 1997 Oct; 57(19):4360-7. PubMed ID: 9331099
[TBL] [Abstract][Full Text] [Related]
5. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.
Courjal F; Cuny M; Rodriguez C; Louason G; Speiser P; Katsaros D; Tanner MM; Zeillinger R; Theillet C
Br J Cancer; 1996 Dec; 74(12):1984-9. PubMed ID: 8980401
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
7. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
8. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
9. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O
J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891
[TBL] [Abstract][Full Text] [Related]
10. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
[TBL] [Abstract][Full Text] [Related]
11. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
12. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
Cordon-Cardo C; Latres E; Drobnjak M; Oliva MR; Pollack D; Woodruff JM; Marechal V; Chen J; Brennan MF; Levine AJ
Cancer Res; 1994 Feb; 54(3):794-9. PubMed ID: 8306343
[TBL] [Abstract][Full Text] [Related]
13. [Study of mdm2 gene amplification in primary breast tumors].
Fontana X; Ferrari P; Abbes M; Monticelli J; Namer M; Bussière F
Bull Cancer; 1994 Jul; 81(7):587-92. PubMed ID: 7742600
[TBL] [Abstract][Full Text] [Related]
14. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification.
Courjal F; Theillet C
Cancer Res; 1997 Oct; 57(19):4368-77. PubMed ID: 9331100
[TBL] [Abstract][Full Text] [Related]
15. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis.
Seshadri R; Leong AS; McCaul K; Firgaira FA; Setlur V; Horsfall DJ
Int J Cancer; 1996 Apr; 69(2):135-41. PubMed ID: 8608982
[TBL] [Abstract][Full Text] [Related]
16. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
18. ERBB2 amplification in breast cancer with a high rate of proliferation.
Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
[TBL] [Abstract][Full Text] [Related]
19. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
Isola J; Visakorpi T; Holli K; Kallioniemi OP
J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
[TBL] [Abstract][Full Text] [Related]
20. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]